CCL2 is one such pro-inflammatory molecule that could be targeted for anti-inflammatory strategies since CCL2 blockade strategy has already been implemented clinically in breast and prostate cancer immune-therapy [15,16]. Here, CCL2 is linked to prostate carcinoma.